Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaAlterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myelomaThe clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myelomaAscorbic Acid Potentiation of Arsenic Trioxide Anticancer Activity Against Acute Promyelocytic Leukemia.Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trialPhase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network studyArsenic trioxide - An old drug rediscovered.Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.Intravenous Vitamin C and Cancer: A Systematic Review.Physiologic Doses of Ascorbic Acid Increase Arsenic Trioxide Toxicity in Human Jurkat -T Lymphoma CellsASCORBIC ACID - MODULATION OF ARSENIC TRIOXIDE TOXICITY: IMPLICATION FOR THE CLINICAL TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIASystematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic.A combination of two antioxidants (an SOD mimic and ascorbate) produces a pro-oxidative effect forcing Escherichia coli to adapt via induction of oxyR regulon.Melphalan: old and new uses of a still master drug for multiple myeloma.From the bench to the bedside: emerging new treatments in multiple myeloma.Differential effect of ascorbic acid and n-acetyl-L-cysteine on arsenic trioxide-mediated oxidative stress in human leukemia (HL-60) cells.Current trends in multiple myeloma management.Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.The evolving use of arsenic in pharmacotherapy of malignant disease.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.Cbl-b-dependent degradation of FLIP(L) is involved in ATO-induced autophagy in leukemic K562 and gastric cancer cells.Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism.A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.Animal models of multiple myeloma and their utility in drug discovery.Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.
P2860
Q24605527-E71A213A-EAED-4BC8-B5B0-3EBF50504E1EQ28484542-C4A56411-58B4-4DA8-9BCE-A7787DE1DFD6Q33422349-E94665A1-4F14-4C9D-A265-E5FD06D23701Q33588205-D33C420A-ACB3-49F5-959B-499F7B85237DQ33659224-C82E7EDA-63C3-4D6D-9F9D-6D5D565C3F50Q33956059-8FB35554-C9EA-442E-AE98-EB6709E2B56CQ33962155-CE42E8C6-3AAF-4F18-8271-1ECD92EF4296Q34054167-58205BB8-C843-40F8-A5BA-7031BAA6A81AQ34580540-0301BE51-A8BF-4AFC-9ED4-0FFCE864F6F3Q35175163-009D4DAF-2EA2-48ED-9BFF-545B243EE6C2Q36078801-D0C3AFCB-909B-4CCA-B66A-5DB6435F3A37Q36253262-FEF86465-629E-4B01-8C2E-568BCAEE8EDAQ36371410-C2070810-1931-4F65-A58C-4A2FFDA2E748Q36839447-13129EE4-E856-4764-A8F4-8CF32558391DQ36916889-DFD80652-4BF3-4C45-87BF-788CCC500651Q37028598-6018B652-B1A6-4FE0-A7C6-B01FBA2F346CQ37182377-24F9F1D2-9618-4602-BE8C-9766B825ABB6Q37183557-5AAC3835-32F2-4986-BA24-92885A37789EQ37486703-2D061DAE-B580-42E0-BEE3-EA0FEC2A68D9Q38089629-829F6509-EC59-423F-A1AC-977DB6E315CEQ38095526-3B29189C-1C55-40B4-9B45-AD472B650B0AQ38253354-E9797740-609D-49FB-94ED-311FF5F18EB7Q39299390-D0068132-9BC2-42C0-BBDB-70383C9BE2B7Q40009277-E33454A0-A0A5-4102-BFF3-44290A5544D6Q41385777-669CB477-DAE7-400A-B5F2-29C3DDC66D94Q46487123-4537CF94-5A83-40D5-908D-5C6B4726C677Q51515954-FE6B78B9-804E-4787-8276-7B39789CC59A
P2860
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Efficacy and safety of melphal ...... e, phase II, single-arm study.
@en
type
label
Efficacy and safety of melphal ...... e, phase II, single-arm study.
@en
prefLabel
Efficacy and safety of melphal ...... e, phase II, single-arm study.
@en
P2093
P2860
P1476
Efficacy and safety of melphal ...... e, phase II, single-arm study.
@en
P2093
Alberto Bessudo
David Siegel
Delina Ferretti
Edward Stadtmauer
Howard S Yeh
J Talisman Pomeroy
James R Berenson
Jose Lutzky
Joseph Volk
Kit Russell
P2860
P304
P356
10.1111/J.1365-2141.2006.06280.X
P407
P577
2006-10-01T00:00:00Z